Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Mobile health clinics in a rural setting: a cost analysis and time motion study of La Clínica in Oregon, United States.
BMC Health Serv Res
January 2025
University of California, San Francisco Institute for Health & Aging, #123K, 490 Illinois Street, San Francisco, CA, 94158, USA.
Background: Mobile Health Clinics (MHCs) are an alternate form of healthcare delivery that may ameliorate current rural-urban health disparities in chronic diseases and have downstream impacts on the health system by reducing costs. Evaluations of providers' time allocation on MHCs are scarce, hindering knowledge transfer related to MHC implementation strategies.
Methods: Retrospective economic cost was assessed using business ledgers and expert assessments in 2023 US Dollar (USD) from 2022 to 2023.
Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC).
Infect Dis Ther
January 2025
Global Research and Medical, Ferring Pharmaceuticals, Kastrup, Denmark.
Recurrent Clostridioides difficile infection (rCDI) is a major cause of increased morbidity, mortality, and healthcare costs. Fecal-microbiota-based therapies are recommended for rCDI on completion of standard-of-care (SoC) antibiotics to prevent further recurrence: these therapies include conventional fecal-microbiota transplantation and the US Food and Drug Administration-approved therapies REBYOTA® (RBL) and VOWST Oral Spores™ (VOS). As an alternative to microbiota-based therapies, bezlotoxumab, a monoclonal antibody, is used as adjuvant to SoC antibiotics to prevent rCDI.
View Article and Find Full Text PDFCost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
J Neurol
January 2025
Department of Neurology, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Background: Natalizumab (NAT) is an established disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, its use involves complex decision-making, often leading to initial use of lower efficacy therapies. Recently, the first biosimilar NAT was approved, enabling competitive pricing.
View Article and Find Full Text PDFLong-term health consequences and costs of changes in alcohol consumption in England during the COVID-19 pandemic.
PLoS One
January 2025
HealthLumen Ltd, London, United Kingdom.
Background And Aims: The COVID-19 pandemic led to changes in alcohol consumption in England. Evidence suggests that one-fifth to one-third of adults increased their alcohol consumption, while a similar proportion reported consuming less. Heavier drinkers increased their consumption the most and there was a 20% increase in alcohol-specific deaths in England in 2020 compared with 2019, a trend continuing through 2021 and 2022.
View Article and Find Full Text PDFGround Reaction Forces and Joint Moments Predict Metabolic Cost in Physical Performance: Harnessing the Power of Artificial Neural Networks.
Appl Sci (Basel)
June 2024
Department of Biomechanics and Center for Research in Human Movement Variability, University of Nebraska at Omaha, Omaha, NE 68182, USA.
Understanding metabolic cost through biomechanical data, including ground reaction forces (GRFs) and joint moments, is vital for health, sports, and rehabilitation. The long stabilization time (2-5 min) of indirect calorimetry poses challenges in prolonged tests. This study investigated using artificial neural networks (ANNs) to predict metabolic costs from the GRF and joint moment time series.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!